http://www.biospace.comBioSpace RSS GeneratorTue, 18 Jun 2013 23:48:33 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20130617006399&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>PARIS--(BUSINESS WIRE)--Ipsen (Euronext: IPN; ADR: IPSEY) today announced the results of an international phase IIIB study, PRIMARYS, assessing an investigational use of Somatuline Autogel (lanreotide) 1...Tue, 18 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/17/554326/0/en/First-patient-dosed-in-new-phase-III-study-targeted-towards-a-future-clinical-indication-expansion-for-Zubsolv.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Uppsala, Sweden June 17, 2013 - Orexo AB announces today that the firstpatient has been dosed with Zubsolv in a phase III study for a new clinicalindication for Zubsolv.<br><br>Help employers find...Mon, 17 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130616005101&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (STO:ORX) announces today that the first patient has been dosed with Zubsolv in a phase III study for a new clinical indication for Zubsolv. Currently...Mon, 17 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20130615005030&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>STOCKHOLM--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced results from two ongoing clinical trials of Jakafi (ruxolitinib), an oral JAK1 and JAK2 inhibitor that is FDA-approved for the treatment...Mon, 17 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/13/553934/10036120/en/Immunomedics-Presents-Epratuzumab-s-Mechanism-of-Action-in-Systemic-Lupus-Erythematosus.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>MADRID, Spain, June 13, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment...Thu, 13 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299819&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Barcelona, Spain, June 5, 2013 - Ferrer, a privately-held Spanish pharmaceutical company with full vertical integration from R&D to distribution, announces today that it has successfully completed a phase III...Wed, 12 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299831&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>BOUDRY, Switzerland (June 12, 2013) Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced 52-week results from PALACE 1, the Companys first phase III...Wed, 12 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=299873&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div class"xn-content"><p><span class"xn-location">MADRID</span>, <span class"xn-chron">June 12, 2013</span> /PRNewswire/ --Janssen Biotech, Inc. announced today new five-year data from three pivotal Phase...Wed, 12 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20130608005008&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>INGELHEIM, Germany--(BUSINESS WIRE)--New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir plus pegylated interferon and ribavirin (PegIFN...Mon, 10 Jun 2013 12:00:00 AM GMTonline.wsj.com/article/BT-CO-20130604-700544.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>AstraZeneca announces top-line results from Phase III OSKIRA Trials of FOSTAMATINIB and decision not to proceed with regulatory filings</font></b><br><br>June 04, 2013 -- Rights to the...Thu, 06 Jun 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/06/06/552505/0/en/Primary-efficacy-and-safety-data-from-four-phase-III-Japanese-studies-of-Simeprevir-presented-at-The-Japan-Society-of-Hepatology.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Stockholm, Sweden Medivir AB (OMX: MVIR) reports that its partner JanssenPharmaceutical R&D Ireland (Janssen) today announced primary efficacy and safetyresults from four Japanese phase III clinical studies...Thu, 06 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20130603005747&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>INGELHEIM, Germany--(BUSINESS WIRE)--The LUME-Lung 1 Phase III clinical trial results showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor, extended life by 2.3 months...Mon, 03 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130603006028&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>CHICAGO & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) today reported results from a Phase 1 study evaluating the safety, tolerability, and maximum tolerated dose (MTD) of...Mon, 03 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130603005436&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced several analyses of a phase III clinical trial of ABRAXANE (paclitaxel protein...Mon, 03 Jun 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130603005918&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced updated data from MM-003, the Companys phase III international...Mon, 03 Jun 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=298003&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b> </font></b><br><br>LAUSANNE, Switzerland--(BUSINESS WIRE)--Alexion Pharma International Srl, a subsidiary of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the U...Thu, 30 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=298301&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia</font></b>...Thu, 30 May 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130529_1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>by Richard Daverman, PhD</p><p>May 29, 2013 -- Beijing Vigoo Biological, a vaccine-focused subsidiary of China National Biotec Group, reported that its Enterovirus 71 vaccine was effective in up to 90% of...Thu, 30 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/30/550727/10034456/en/Amarin-Announces-Additional-Effects-of-Vascepa-R-on-Lipoprotein-Particle-Concentration-From-the-ANCHOR-Study-Presented-at-the-National-Lipid-Association-2013-Annual-Scientific-Sess.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve...Thu, 30 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/29/550325/0/en/NeuroVive-European-phase-III-study-approaches-its-final-stage.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company,announces that the ongoing international multicenter phase III study on thecompanys drug candidate CicloMulsion (the CIRCUS...Wed, 29 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297844&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>BAGSVAERD, Denmark I 23 May 2013 I Novo Nordisk today announced the headline results from a 56-week double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight...Tue, 28 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130528005288&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>BARCELONA, Spain--(BUSINESS WIRE)--SALVAT announced that clinical trial enrollment has completed for the Phase III study evaluating the efficacy and safety of a new otic solution containing Ciprofloxacin and...Tue, 28 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297810&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Aberdeen, United Kingdom, 22 May 2013 Coinciding with Dementia Awareness Week in the UK, TauRx Therapeutics Ltd announced that the first of more than 100 UK patients have enrolled in the global Phase 3 clinical...Thu, 23 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297364&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat</font></b><br><br>Berlin, May 20, 2013 Bayer HealthCare today announced positive data from...Wed, 22 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/21/548678/0/en/Primary-efficacy-and-safety-findings-from-phase-III-study-of-Simeprevir-in-treatment-experienced-patients-demonstrate-sustained-virologic-response.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Stockholm, Sweden Medivir AB (OMX: MVIR) reports that its partner Janssen R&DIreland (Janssen) today announced primary efficacy and safety results from theglobal phase III PROMISE study. Results demonstrated...Tue, 21 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297430&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Chippenham, UK 21 May 2013: Vectura Group plc (LSE: VEC) (Vectura), confirms theinformation released today by Novartis announcing that new data from the chronic obstructivepulmonary disease (COPD) portfolio...Tue, 21 May 2013 12:00:00 AM GMTStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><b>Roche's obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer</b><br><br>Basel, 16 May 2013 -- Roche (SIX: RO...Mon, 20 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297084&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis</font></b><br><br>Paris, France - May 17, 2013- Sanofi (EURONEXT: SAN and...Mon, 20 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/20/548304/0/en/Final-STRATO-Clinical-Study-Data-Demonstrates-Potential-for-LCP-TacroTM-to-Improve-Tacrolimus-Induced-Tremors.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro to improve tacrolimus-induced tremors in stable kidney transplant patients. ...Mon, 20 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/18/548245/0/en/Vortioxetine-clinical-phase-III-data-show-significant-improvement-in-symptoms-of-major-depression.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Valby, Denmark, 18 May 2013 - H. Lundbeck A/S (Lundbeck) and partner Takeda Pharmaceutical Company Limited (Takeda) today announced that the companies will be presenting new data on four pivotal studies on vortioxetine...Mon, 20 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297310&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>PARIS--(Marketwired - May 20, 2013) - <p><br><b>Launch of a phase 3 clinical trial in the treatment of Alzheimer's disease with masitinib</b> <p><b>First patients recruited...Mon, 20 May 2013 12:00:00 AM GMThttp://www.thepharmaletter.com/file/122173/astrazeneca-plans-to-move-three-cancer-drug-candidates-into-ph-iii.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>AstraZeneca Plc (AZN) will move three experimental cancer treatments into late-stage development as generic competition for its best-selling drugs intensifies. The U.K.s second-biggest drugmaker is advancing...Fri, 17 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=297156&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced thecompletion of paradigm&#8482; 2, the first phase 3 trial with a long-actingFIX derivative...Fri, 17 May 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/05/15/health-cancer-roche-idUSL6N0DV2P220130515Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>ZURICH, May 15 (Reuters) - Swiss drugmaker Roche hopes data published this week will show it has a viable follow-on product to help fend off cheaper competition for its best-selling cancer drug, which loses...Thu, 16 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=296756&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br> <div class"xn-content"><p><span class"xn-location">PARIS</span> and <span class"xn-location">TARRYTOWN, N.Y.</span>, <span class"xn-chron">May 15, 2013</span> /PRNewswire/ -- Sanofi (EURONEXT: SAN and...Wed, 15 May 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/05/13/546520/0/en/U-S-FDA-grants-priority-review-to-Simeprevir-for-combination-treatment-of-genotype-1-chronic-hepatitis-C.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Stockholm, Sweden Medivir AB (OMX: MVIR) today announces that the U.S. Foodand Drug Administration (FDA) has granted Priority Review to the New DrugApplication (NDA) by Janssen for simeprevir (TMC435...Mon, 13 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130513005818&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIR-B) today announces that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) by Janssen...Mon, 13 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=295796&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>(Thomson Reuters ONE via COMTEX) -- Actelion Pharmaceuticals Ltd / Actelion provides update on Phase III GRIPHON study with selexipag in pulmonary arterial hypertension - Study continues . Processed and transmitted...Wed, 08 May 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20130506006296&newsLang=enStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that statistical significance was achieved for the primary endpoint of ACR...Tue, 07 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294727&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>BASEL, SWITZERLAND--(Marketwired - April 29, 2013) - Basilea Pharmaceutica AG /Basilea reports presentation of new data on anti-infective drug candidatesaddressing drug...Mon, 29 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294424&full=1<div id"releaseBody"><p>LUND, SWEDEN and PARIS--(Marketwired - April 25, 2013) - <p><br> * Primary PFS analysis now expected at the same time as first interimoverall survival analysis in 2014<p>Active Biotech (NASDAQ OMXNORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced thatthecompanies have updated the analysis plan for the 10TASQ10 trial, a globalPhase...Thu, 25 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294092&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>AMSTERDAM--(BUSINESS WIRE)--April 23, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating...Tue, 23 Apr 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/04/19/us-anaemia-pill-idUSBRE93I0GH20130419Japan's Astellas Pharma and Britain's GlaxoSmithKline are competing to develop a new kind of medicine that boosts production of red blood cells by making the body think it is at high altitude. Their experimental drugs - both given as pills - could create a major new market in treating anemia and other serious conditions, including circulatory problems and wound damage. They may also attract unscrupulous...Mon, 22 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293961&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&source"news-signup"">free GenePool newsletter</a> today!<br><br>April 2013 -- SCM Pharma will assist BTG in preparation for the commercial launch of Varisolve (polidocanol endovenous microfoam (PEM)), after providing clinical development consultancy for the product...Mon, 22 Apr 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.b30484b92e958b11adda3242e6908a0c/index.jsp?ndmViewId=news_view&newsId=20130417005827&newsLang=enTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) today presented data from a sub-analysis of a Phase III clinical trial of Milprosa (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization (IVF). The results were presented at the 61st Annual Meeting of the Pacific Coast Reproductive Society (PCRS).Wed, 17 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=293327&full=1BARCELONA & NEW YORK--(BUSINESS WIRE)-- Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide, (LAMA) and formoterol fumarate (LABA) delivered by Almiralls inhaler Genuair (Pressair in the USA).</p><p>Both combinations...Tue, 16 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=292712&full=1April 8, 2013 -- InDex Pharmaceuticals, a Swedish biopharmaceutical company, has completed patient enrollment for its phase III COLLECT study of Kappaproct. The multinational, randomized, double-blind, placebo-controlled study reached the recruitment goal of 120 patients with treatment-refractory ulcerative colitis (UC). InDex is expecting final study results in mid-2014.</p><p>The phase III trial...Mon, 08 Apr 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291964&full=1<div id"releaseBody"><p>SAN FRANCISCO, CA and TOKYO--(Marketwire - April 01, 2013) - Medivation, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerMDVN">MDVN</a>) and Astellas Pharma Inc. (TSE: 4503) today announced that the companies have established an updated interim analysis plan for the PREVAIL trial, a global Phase 3 clinical trial evaluating XTANDI&#174; (enzalutamide...Mon, 01 Apr 2013 12:00:00 AM GMTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today interim results from the first year of the extension study of LEMTRADA (alemtuzumab), being developed for the treatment for multiple sclerosis (MS).</p><p>In this analysis of the first year of the extension study, relapse rates and sustained accumulation of disability remained low among...Fri, 22 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291180&full=1JERUSALEM & LUND, Sweden--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today top-line results from the open-label extension of the Phase III ALLEGRO study that assessed the progression of disability and safety of oral laquinimod in early versus delayed-start relapsing-remitting multiple sclerosis (RRMS) patients. The study compared...Thu, 21 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=291135&full=1Lyon, France, March 19, 2013 - Adocia (NYSE Euronext Paris: FR0011184241 - ADOC), a biotechnology company specialized in the development of best-in-class medicines from already approved therapeutic proteins announces today the phase III development program of its product, BioChaperone(R) PDGF-BB for the treatment of diabetic foot ulcer (DFU). The European Medicines Agency (EMA) issued positive scientific...Wed, 20 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290718&full=1<div id"releaseBody"><p>BAGSVAERD, DENMARK--(Marketwire - March 18, 2013) - <p><br>Company announcement No 19 / 2013:<p><a href"http://hugin.info/2013/R/1685937/552525.pdf">http://hugin.info/2013/R/1685937/552525.pdf</a><p>This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:<p>(i) the releases...Tue, 19 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130317005084&newsLang=enTOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573) is pleased to announce the start of the patient enrollment of a Phase 3 clinical study with Unoprostone(note 1) (development code UF-021) ophthalmic solution that are being developed in our company for the treatment of retinitis pigmentosa(note 2). The Phase 3 clinical study with UF-021 ophthalmic solution for treatment of retinitis pigmentosa (ClinicalTrials...Mon, 18 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290842&full=1Vienna, Austria, March 18, 2013 / B3C newswire / - Anagrelide a selective platelet lowering agent is not inferior compared to hydroxyurea in preventing disease related complications in patients with WHO-ET. ANAHYDRET study data now provide evidence that anagrelide can be considered as first line therapy for lowering of platelet count in WHO-ET.</p><p>High platelet counts in essential thrombocythemia...Mon, 18 Mar 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130314BEIJING</span>, <span class"xn-chron">March 14, 2013</span> /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in <span class"xn-location">China</span>, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Enterovirus 71 ("EV71") vaccine against hand, foot and mouth...Fri, 15 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290691&full=1Vienna, March 15, 2013 - The pooled analysis of data from two clinical studies has once again proven the effectiveness of an innovative antiviral nasal spray used to treat the common cold. Both the duration of cold infections and the number of patients with symptoms were clearly reduced by the use of the nasal spray developed by the Viennese biotech company Marinomed. The effectiveness of the safe...Fri, 15 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=290290&full=1Paris, March 12, 2013 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the initiation of Loramyc/Oravig Phase III clinical trial for the treatment of oropharyngeal candidiasis by its Japanese partner Sosei. This is the final step before registration of the drug by Japanese authorities...Tue, 12 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289994&full=1SAN FRANCISCO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced data from the Phase 4 TERISA (Type 2 Diabetes Evaluation of Ranolazine In Subjects With Chronic Stable Angina) study, which demonstrated that the addition of ranolazine to background antianginal therapy in chronic angina patients with type 2 diabetes significantly reduced the frequency of weekly angina episodes compared to...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.thepharmaletter.com/file/120555/eisai-slams-german-decision-on-fycompa-takeda-files-vedolizumab-with-ema.htmlThe German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system in Germany, has that it considers the additional benefit of Japanese drug major Eisais (TYO: 4523) epilepsy drug Fycompa (perampanel) unproven when compared to two other treatments as defined by the G-BA. CS PharmaValues NPV Analysts at Credit Suisse have a net present value for Fycompa in Europe...Mon, 11 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289886&full=1Berlin, Germany, March 8, 2013 -Bayer HealthCare announced today the initiation of the PIONEER AF-PCI study, a Phase IIIb clinical study of its oral anticoagulant Xarelto (rivaroxaban) to investigate how best to treat patients with non-valvular atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stent placement.</p><p>The PIONEER AF-PCI study will enroll approximately...Fri, 08 Mar 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130306005054&newsLang=enJERUSALEM & LUND, Sweden, Mar 06, 2013 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. TEVA 3.32% and Active Biotech (nasdaq omx nordic:ACTI) announced today enrollment of the first patient in the CONCERTO study - the third Phase III placebo-controlled study designed to evaluate the efficacy, safety and tolerability of once-daily oral laquinimod in patients with relapsing-remitting multiple...Fri, 08 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289442&full=1ATLANTA</span> and <span class"xn-location">BRUSSELS</span>, March 5, 2013 /PRNewswire/ --<b> regulated information </b> UCB today announced positive results of a Phase 3 study designed to evaluate the efficacy and safety of conversion to lacosamide monotherapy in adult patients with partial-onset seizures with or without secondary generalization compared with a historical control. The study met its...Tue, 05 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289250&full=1JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVA) today announced the publication of results of the Phase III clinical trial of Milprosa (progesterone) vaginal ring in Fertility and Sterility. The study compared the efficacy and safety of once-weekly Milprosa to daily 8 percent progesterone vaginal gel for luteal phase support in in vitro fertilization (IVF) and found that clinical...Mon, 04 Mar 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=289000&full=1<div id"releaseBody"><p>BRISBANE, AUSTRALIA--(Marketwire - February 28, 2013) - <p><br><ul><li>415 patients recruited; recruitment now closed </li><li>Participation in sub-study outperformed expectations </li><li>Results expected early 2014 </li></ul><p>Brisbane drug discovery and development company Alchemia Limited (ASX: ACL) has completed enrolment of patients in a pivotal Phase...Thu, 28 Feb 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130228005464&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)--With the enrollment of the first patient, Boehringer Ingelheim is pleased to announce on international Rare Disease Day, the initiation of a Phase III study (POLO-AML-2) investigating volasertib*, a selective and potent polo-like kinase (Plk) inhibitor, in combination with chemotherapy, in patients with acute myeloid leukaemia (AML) ineligible for intensive therapy...Thu, 28 Feb 2013 12:00:00 AM GMThttp://www.rttnews.com/2063322/merck-kgaa-late-stage-trial-of-cilengitide-fails-to-meet-primary-endpoint.aspx?type=qf&utm_source=google&utm_campaign=sitemapMerck KGaAs (MRK) experimental tumor- fighting drug cilengitide failed to help patients with a form of brain cancer in a late-stage clinical trial, adding to recent drug-development setbacks for the company. The medicine didnt significantly increase survival in patients with newly diagnosed glioblastoma when added to standard chemotherapy, the Darmstadt, Germany-based drugmaker said in a statement...Tue, 26 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=288718&full=1Regensburg, Germany, February 26, 2013 / B3C newswire / - The biopharmaceutical company Antisense Pharma GmbH, today announced its revised corporate and development strategy, receiving full support from its main investors.</p><p>The updated corporate strategy focuses on streamlining the organization to meet its current business objectives and strengthen key senior management positions in light of...Tue, 26 Feb 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130225006100&newsLang=enVIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that its Taiwanese partner, Orient Europharma, has added two additional Taiwanese clinical centers in CEL-SCIs Phase III head and neck cancer clinical trial for Multikine (Leukocyte Interleukin, Injection), the Companys flagship investigational immunotherapy. The first center is the China Medical University Hospital...Mon, 25 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287844&full=1<div id"releaseBody"><p>OSLO, NORWAY--(Marketwire - February 15, 2013) - <p><br>Intended for US Media only<p>Abstracts #11 &amp; #19<p>Algeta ASA (OSE: ALGETA) announces that furthersub-analyses of data from the phase III ALSYMPCA study of radium Ra 223dichloride (radium-223) in castration-resistant prostate cancer (CRPC)patientshave been presented at the 2013 Genitourinary Cancers...Fri, 15 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287495&full=1CAMBRIDGE, Mass. and TOKYO, Japan, February 12, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median...Thu, 14 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=287156&full=1HONOLULU--(BUSINESS WIRE)-- POZEN Inc. (POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole, in patients with previous cerebrovascular disease. These data were presented at the American Heart Association...Fri, 08 Feb 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130208005166&newsLang=enWARSAW, Poland--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia...Fri, 08 Feb 2013 12:00:00 AM GMThttp://www.reuters.com/article/2013/01/31/roche-ga-idUSL5N0B01HF20130131Roche's GA101 drug significantly improved progression-free survival in people with chronic lymphocytic leukaemia (CLL), giving the Swiss drugmaker the first signal it may have a viable successor to its current best-selling medicine. Roche is banking on the success of GA101 to fend off the threat of so-called biosimilar copies of cancer treatment MabThera, its top seller in 2012 with sales of 6.7 billion...Mon, 04 Feb 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=285434&full=1BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Srl, a subsidiary of Celgene Corporation (CELG), today announced that its phase III clinical trial of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-nave patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in...Thu, 24 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=285465&full=1JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. today announced top-line results of its Phase III clinical program for armodafinil (NUVIGIL) as adjunct therapy in adults with major depression associated with bipolar 1 disorder. While study 3072 demonstrated a numerical improvement, it did not reach statistical significance in meeting its primary endpoint -- to determine whether armodafinil...Wed, 23 Jan 2013 12:00:00 AM GMThttp://www.globenewswire.com/news-release/2013/01/22/517649/10018103/en/Amarin-Announces-Publication-of-Additional-Inflammatory-Marker-Data-From-MARINE-and-ANCHOR-Phase-3-Clinical-Trials-in-the-American-Journal-of-Cardiovascular-Drugs.htmlBEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available electronically through PubMed (available at: http...Tue, 22 Jan 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/template.PAGE/menuitem.ab520ce17e34ab71ff00d635c0908a0c/index.jsp?ndmViewId=news_view&newsId=20130122005270&newsLang=enNIJMEGEN, the Netherlands--(BUSINESS WIRE)--Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs). In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon has reported complete tumor remission. Toxicity experiments conducted to...Tue, 22 Jan 2013 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20130117005088&newsLang=enINGELHEIM, Germany--(BUSINESS WIRE)--Today, Boehringer Ingelheim announced that the first patients have been enrolled in the companys pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso. Boehringer Ingelheims IFN-free investigational polymodal* regimen combines faldaprevir (BI 201335), a next wave once-daily protease inhibitor, and BI 207127, a non-nucleoside...Thu, 17 Jan 2013 12:00:00 AM GMThttp://www.thepharmaletter.com/file/119304/eisaimorphoteks-farletuzumab-fails-on-ovarian-cancer-ph-iii-trial.htmlThe FAR-131 trial of farletuzumab developed by Eisai's US subsidiary Morphotek showed that the drug was unable to improve progression-free survival (PFS) in patients with platinum-sensitive epithelial ovarian cancer who had suffered a first relapse. In the 1,100-patient study, farletuzumab at two doses or placebo were added to a background regimen of carboplatin and a taxane drug such as paclitaxel...Tue, 15 Jan 2013 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20130111by Richard Daverman, PhD</p><p>January 11, 2013 -- Chongqing Zhifei Biological Product Co. has been granted SFDA approval to begin a Phase III trial of an existing product, Mycobacterium Vaccae for Injection (Vaccae), as a vaccine for tuberculosis, a currently unmet need. Vaccae is an immune system modulator that the company currently sells as an adjuvant to treat TB. More details....</p><p...Fri, 11 Jan 2013 12:00:00 AM GMT